California’s powerful health care industry just notched a historic win: The state is going to give it an $11.1 billion infusion to improve care for millions of low-income Medicaid patients.
MindBio Therapeutics Corp. Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials | Psychedelic Invest
MindBio Therapeutics Corp. reported durability data from Phase 2A clinical trials in depressed patients testing MB22001, MindBio’s proprietary self-administered take home microdose of Lysergic Acid